Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN® (lucinactant) Updated Product Specifications
Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN® (lucinactant) Updated Product Specifications
Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN® (lucinactant) Updated Product Specifications
Submitted by
admin
on June 10, 2013 - 11:36am
Source:
CP Wire
News Tags:
Discovery Labs
FDA
Surfaxin
respiratory distress syndrome
Headline:
Discovery Labs Responds to FDA Request for Clarification of Recently Submitted SURFAXIN® (lucinactant) Updated Product Specifications
Do Not Allow Advertisers to Use My Personal information
